Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic Review.

Rahal AK, Badgett RG, Hoffman RM.

PLoS One. 2016 Apr 12;11(4):e0153417. doi: 10.1371/journal.pone.0153417. eCollection 2016.

2.

A System Dynamics Model of Serum Prostate-Specific Antigen Screening for Prostate Cancer.

Palma A, Lounsbury DW, Schlecht NF, Agalliu I.

Am J Epidemiol. 2016 Feb 1;183(3):227-36. doi: 10.1093/aje/kwv262. Epub 2015 Dec 24. Erratum in: Am J Epidemiol. 2016 Mar 15;183(6):597.

PMID:
26702631
3.

Skeletal Metastasis of Unknown Primary Origin at the Initial Visit: A Retrospective Analysis of 286 Cases.

Takagi T, Katagiri H, Kim Y, Suehara Y, Kubota D, Akaike K, Ishii M, Mukaihara K, Okubo T, Murata H, Takahashi M, Kaneko K, Saito T.

PLoS One. 2015 Jun 26;10(6):e0129428. doi: 10.1371/journal.pone.0129428. eCollection 2015.

4.

Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic.

Walker R, Louis A, Berlin A, Horsburgh S, Bristow RG, Trachtenberg J.

Can Urol Assoc J. 2014 Nov;8(11-12):E783-8. doi: 10.5489/cuaj.1970.

5.

Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ.

Eur Urol. 2015 Apr;67(4):619-26. doi: 10.1016/j.eururo.2014.10.010. Epub 2014 Oct 31. Review.

6.

Expected population impacts of discontinued prostate-specific antigen screening.

Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, Cooperberg MR.

Cancer. 2014 Nov 15;120(22):3519-26. doi: 10.1002/cncr.28932. Epub 2014 Jul 25.

7.

Prostate cancer detection by prostate-specific antigen-based screening in the Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection.

Teishima J, Maruyama S, Mochizuki H, Oka K, Ikeda K, Goto K, Nagamatsu H, Hieda K, Shoji K, Matsubara A.

Can Urol Assoc J. 2014 May;8(5-6):E327-32. doi: 10.5489/cuaj.1715.

8.

Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).

Turner EL, Metcalfe C, Donovan JL, Noble S, Sterne JA, Lane JA, Avery KN, Down L, Walsh E, Davis M, Ben-Shlomo Y, Oliver SE, Evans S, Brindle P, Williams NJ, Hughes LJ, Hill EM, Davies C, Ng SY, Neal DE, Hamdy FC, Martin RM; CAP trial group.

Br J Cancer. 2014 Jun 10;110(12):2829-36. doi: 10.1038/bjc.2014.242. Epub 2014 May 27.

9.

Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men.

Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1505-11. doi: 10.1158/1055-9965.EPI-13-1328. Epub 2014 May 6.

10.

What do the screening trials really tell us and where do we go from here?

Etzioni RD, Thompson IM.

Urol Clin North Am. 2014 May;41(2):223-8. doi: 10.1016/j.ucl.2014.01.002. Epub 2014 Feb 19. Review.

11.

Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.

Sequeiros T, García M, Montes M, Oliván M, Rigau M, Colás E, de Torres I, Morote J, Reventós J, Doll A.

Biomed Res Int. 2013;2013:283635. doi: 10.1155/2013/283635. Epub 2013 Nov 25. Review.

12.

Is prostate-specific antigen effective for population screening of prostate cancer? A systematic review.

Lee YJ, Park JE, Jeon BR, Lee SM, Kim SY, Lee YK.

Ann Lab Med. 2013 Jul;33(4):233-41. doi: 10.3343/alm.2013.33.4.233. Epub 2013 Jun 24. Review.

13.

Focal therapy for prostate cancer: rationale and treatment opportunities.

Kasivisvanathan V, Emberton M, Ahmed HU.

Clin Oncol (R Coll Radiol). 2013 Aug;25(8):461-73. doi: 10.1016/j.clon.2013.05.002. Epub 2013 Jun 4. Review.

14.

Men's preferences for prostate cancer screening: a discrete choice experiment.

de Bekker-Grob EW, Rose JM, Donkers B, Essink-Bot ML, Bangma CH, Steyerberg EW.

Br J Cancer. 2013 Feb 19;108(3):533-41. doi: 10.1038/bjc.2013.5. Epub 2013 Jan 29.

15.

Early results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomes.

Yamoah K, Beecham K, Hegarty SE, Hyslop T, Showalter T, Yarney J.

BMC Cancer. 2013 Jan 16;13:23. doi: 10.1186/1471-2407-13-23.

16.

LHRH Agonists for the Treatment of Prostate Cancer: 2012.

Lepor H, Shore ND.

Rev Urol. 2012;14(1-2):1-12.

17.

Prostate-specific antigen screening can be beneficial to younger and at-risk men.

Roobol MJ, Bangma CH, Loeb S.

CMAJ. 2013 Jan 8;185(1):47-51. doi: 10.1503/cmaj.111962. Epub 2012 May 7. No abstract available.

18.

Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes.

Kakehi Y.

Asian J Androl. 2012 May;14(3):361-4. doi: 10.1038/aja.2011.151. Epub 2012 Apr 16. Review.

19.

The impact of PLCO control arm contamination on perceived PSA screening efficacy.

Gulati R, Tsodikov A, Wever EM, Mariotto AB, Heijnsdijk EA, Katcher J, de Koning HJ, Etzioni R.

Cancer Causes Control. 2012 Jun;23(6):827-35. doi: 10.1007/s10552-012-9951-8. Epub 2012 Apr 10.

20.

Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1.

Gulzar ZG, McKenney JK, Brooks JD.

Oncogene. 2013 Jan 3;32(1):70-7. doi: 10.1038/onc.2012.27. Epub 2012 Feb 20.

Items per page

Supplemental Content

Write to the Help Desk